Search

Your search keyword '"Matheron S"' showing total 540 results

Search Constraints

Start Over You searched for: Author "Matheron S" Remove constraint Author: "Matheron S"
540 results on '"Matheron S"'

Search Results

1. Safety of protease inhibitors in HIV-infected pregnant women

2. Immunovirological status in people with perinatal and adult-acquired HIV-1 infection: a multi-cohort analysis from France

10. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

12. Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress?

13. No increased risk of Kaposi sarcoma relapse in patients with controlled HIV‐1 infection after switching protease inhibitor‐based antiretroviral therapy

14. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

15. Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

16. Levels and determinants of breast and cervical cancer screening uptake in HIV‐infected women compared with the general population in France

18. Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis

19. Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis

21. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

23. Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation

24. Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?

25. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018

26. Reaching the Second and Third Joint United Nations Programme on HIV/AIDS 90-90-90 Targets Is Accompanied by a Dramatic Reduction in Primary Human Immunodeficiency Virus (HIV) Infection and in Recent HIV Infections in a Large French Nationwide HIV Cohort

27. Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015

28. Genetic Variability of Long Terminal Repeat Region between HIV-2 Groups Impacts Transcriptional Activity

29. Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Dat’AIDS Cohort Study

30. Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: patient satisfaction and implications for adherence

34. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir

35. HIV Infection and Long‐Term Residual Cardiovascular Risk After Acute Coronary Syndrome

36. Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation

38. Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France

39. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort

40. B7-H6-mediated downregulation of NKp30 in natural killer cells contributes to HIV-2 immune escape

41. Limited HIV-2 reservoirs in central-memory CD4 T-cells associated to CXCR6 co-receptor expression in attenuated HIV-2 infection

42. Fourth meeting of the European Neurological Society 25–29 June 1994 Barcelona, Spain: Abstracts of Symposia and free communications

43. Evaluation des microorganismes pathog’enes intestinaux au cours de I’infection VIH

44. Abstracts

45. Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study

46. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients

47. Mortality in migrants living with HIV in western Europe (1997–2013): a collaborative cohort study

48. Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIRaben-1 subtype B and non-subtype B receiving a salvage regimen

49. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies

50. First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2)

Catalog

Books, media, physical & digital resources